This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
88
Clinical Trial Site
Mount Royal, Canada
RECRUITINGFrequency of Adverse Events
Time frame: Up to 12 months
Concentrations of ALN-6222 in Plasma
Time frame: Predose and up to 3 days postdose
Change from Baseline Protein Markers in Plasma
Time frame: Predose and up to 12 months postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.